Skip to main content
Donate

About Angelman Syndrome

AS Genotypes: Deletion

Angelman Syndrome Genotypes: Deletion (65-75% of cases)

The most common cause of AS is that the UBE3A gene is missing, or deleted, from the maternal copy of chromosome 15.   Because the maternal UBE3A gene is missing and the paternal UBE3A gene is turned off, a person with a deletion of the maternal UBE3A gene does not make any UBE3A protein.

Individuals living with AS deletions are often missing not just UBE3A but also 8-12 other genes. This means they are missing 5-6 MILLION base pairs of DNA on the maternal chromosome 15. The other missing genes also contribute to tonic inhibition, seizures, lighter coloring, and more. All together, this makes the features of those living with AS deletion generally more severe than the other genotypes.

A deletion removes the normal expression of this gene in AS individuals.

A deletion removes the normal expression of this gene in AS individuals

In most individuals, the deletion of UBE3A and the surrounding genes was a random event and NOT inherited from a parent.  The deletion actually occurs when the mother’s eggs are developing, which happens before the mother is even born!  However, in rare cases, the deletion happens during the formation of the egg because of a chromosome difference that the mother carries.  This chromosomal difference increases the possibility of a deletion occurring when eggs are made.  Consequently, chromosomal testing of the mother is recommended. 

If the mother has chromosomal testing that is typical, the chance for a future child to have the deletion that causes AS is predicted to be less than 1%.  This means that more than 99% of the time, future children will not have the deletion that causes AS.  The chance is not zero because there have been rare cases reported where the woman had multiple eggs with the deletion or actually carried the deletion in some of her body cells. 

All the pharmaceutical companies in our space have stated that they want to have the most consistent group for the earliest phases of clinical trials (Phase 1/2), and in many cases they want the most severely affected to start with. That is generally considered to be those with deletions.

All 4 of the current trials underway are enrolling patients with AS deletions. Visit this page to learn more about them.

Connect with other AS Deletion families by writing to us here: community@cureangelman.org

Still have questions?

If you are wondering about your specific chance to have a child with a genetic variant that causes AS, it is very important to consult a genetics professional like a genetic counselor or geneticist. The chance varies depending upon the test results of the person living with AS and the testing that was performed on the parent(s). The information provided here may be helpful but it is not specific to your family and is not meant to replace genetic counseling.

Angelman Syndrome News

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.